Clarins
This article was originally published in The Rose Sheet
Executive Summary
Net profit rose 11.2% at constant exchange rates to $116.4 mil. (€1=$1.20) in 2005, due in part to "a sharp decrease in net interest expense as a result of...debt reduction," in addition to a reduction in average current tax rate and unrealized gains from its stake in L'Occitane, French beauty firm reports March 24. Net profit was up 11.4% on a like-for-like basis. Operating profit rose 4.5% to $152.1 mil. Clarins' Beauty operating profit advanced 9.4%, or 9% like-for-like, to $112.5 mil. during the year, while Perfumes division operating profit declined 7.3%, or 6.4% on a like-for-like basis, to $39.6 mil. Clarins reported 2005 net sales in February (1"The Rose Sheet" Feb. 6, 2006, p. 6)...
You may also be interested in...
Clarins Will Step Up Skin Care Offerings To Grow Segment In ’06
Clarins is targeting its skin care business as a primary area of growth this year, the French beauty firm announced in a Feb. 3 sales release
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.